Thursday, 3 July 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 03 July 2025
News

Forget the hype: Oncology still No 1

Posted 30 July 2024 AM

For all the buzz around obesity, oncology will remain the most valuable therapy area in 2030 with over US$370 billion in forecast sales across all products with Johnson & Johnson at the top of the company league.

That is more than twice the totals for endocrinology (obesity & diabetes), immunology and resurgent CNS, according to Evaluate's World Preview 2024 - Pharma's Growth Boost report.

To see the whole article, please login

Popular

Two new Country Leaders named
How generous was pharma in 2024?
AZ pulls breast cancer drug
Industry boss announces exit
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (10)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home